Professor Kausik Kumar Ray

Personal Details

Name:	**Professor Kausik Kumar RAY**	**Nationality:**	British
Address:	74 Ferndale Road, London SW4 7SE	**DoB:**	4th May 1967
Tel:	+44 7960 181 754	**GMC no:**	3431090
Email:	koshray@gmail.com k.ray@imperial.ac.uk	**CCT Aug 2003:**	Cardiology/ General Internal Medicine
Website:	http://www.imperial.ac.uk/people/k.ray	**Specialist Register:**	Cardiology/ General Internal Medicine: April 2004

Degrees and Qualifications Held

2015	FRCP (Ed)	2007	MPhil (Epidemiology), *University of Cambridge*
2013	FAHA	2004	MD, *University of Sheffield*
2011	FRCP (Lon)	1994	MRCP, *UK*
2008	FESC	1991	MBChB, *University of Birmingham (Medical School)*
2008	FACC		

Employment History

Nov 2021 **Director of Imperial Clinical Trials Unit: Global,** *Imperial College London*

May 2018 **Deputy Director,** *Imperial Clinical Trails Unit (ICTU)*

Feb 2015 **Professor of Public Health,** *Imperial College London*
Director of the Imperial Centre for Cardiovascular Disease Prevention (ICCP), Department of Primary Care and Public Health, School of Public Health
Honorary Consultant Cardiologist, *Imperial College Healthcare NHS Trust*

Jun 2010 **Professor of Cardiovascular Disease Prevention**
Division of Cardiovascular Sciences, *St George's, University of London*
Honorary Consultant Cardiologist, *St George's Hospital NHS Trust*

Jun 2006 **British Heart Foundation Intermediate Fellow**
Department of Public Health and Primary Care, *University of Cambridge*
Honorary Consultant Cardiologist, *Addenbrookes Hospital*

Apr 2006 **Locum Consultant Cardiologist,** *Walsall Manor Hospital*

Jan 2004 **British Heart Foundation International Fellow**
Harvard Medical School, USA

International and National Leadership Positions

2022	Co-chair of the World Heart Federation Cholesterol Roadmap 2022 update
2022	G20 Health and Development Partnership under the auspices of the WHO (representing the Council for Heart Health as Chair)
2021-2024	President of the European Atherosclerosis Society
2017-2020	Board Member of the Executive Committee of the European Atherosclerosis Society
2022	Senior Advisory to NHS England Accelerated Access Collaboration on Lipid-Lowering Therapies
2019	National lead for Cardiovascular Disease, NIHR ARC
2019	Clinical Lead for Research, HDR UK Digital Innovation Hub NW London (DISCOVER NOW)
2018	World Heart Federation Task Force for FH, Co-chair
2015-2022	External Expert Advisor to NICE on Lipid Modification Therapies representing the British Cardiovascular Society ESC Nucleus Work Group, Prevention ESC Nucleus Working Group, Thrombosis

Clinical Trials: National and International Leadership of multi-centre trials

Savor TIMI 53: ***National Lead Investigator and Executive Committee Member***
Multi-centre study assessing if saxagliptin reduces risk of CV events, alone or with other diabetes drugs

Dal OUTCOMES 2: ***Executive Committee member***
A multi-centre study evaluating safety and efficacy of dalcetrapib in patients hospitalized with high CV Risk

Dal ACUTE: ***Principal Investigator***
A multi-centre study evaluating safety and efficacy of dalcetrapib on HDL cholesterol levels and function post myocardial infarction

Solid TIMI 52: ***National Lead Investigator and Steering Committee Member***
Multi-centre study to test whether darapladib can safely lower the chances of having a CV event when treatment is started within 30 days after an acute coronary syndrome.

Declare TIMI 58: ***National Lead Investigator and Steering Committee Member***
Multi-centre study to test if dapagliflozin, when added to a patient's current anti-diabetes therapy, effectively reduces CV events (heart attack, ischemic stroke and CV related death) compared with placebo

Odyssey Outcomes: ***National Lead Investigator***
Multi-centre study comparing effect of alirocumab with a placebo on the occurrence of CV events in patients who have experienced an Acute Coronary Syndromes

SONAR: ***Events Adjudication Committee Member***
An RCT of a novel endothelin inhibitor atrasentan on CV death or end stage renal disease

TIME Study: Data Safety Monitoring Committee.
A trial of evening vs morning anti-hypertensive therapies on CV outcomes

ACCENTUATE: ***Executive Committee Member***
A trial of Anacetrapib on Lipid levels among FH/dyslipidemia patients intolerant of current therapies

CAMELLIA TIMI 61: ***Steering Committee Member***
Phase 3 trial of novel agent for weight loss improvement of metabolic traits, CVD outcomes

THEMIS: ***National Lead Investigator and Steering Committee Member***
Assessing the effect of Ticagrelor in stable CHD

STRENGTH: ***National Lead Investigator and Executive Committee Member***
Omega 3 Fatty acids for the Prevention of CVD in patients with High Triglycerides

CARAT: ***Executive Committee Member***
Efficacy of HDL mimetic on atheroma burden on intravascular ultrasound

BETONMACE: ***Chair of International Executive Committee and PI***
Efficacy and safety of apabetalone on epigenetic modification using BET protein inhibition on CV outcomes

ORION 1: ***Principal Investigator and Co-chair of the EC***
Phase 2 RCT assessing efficacy of novel intervention with siRNA therapy to PCSK9 on lipids

ODYSSEY Diabetes 1: ***Executive Committee member*** *(Completed 2017. Sanofi Regeneron)*
Phase 3 RCT assessing efficacy of Alirocumab on lipids in patients with atherogenic dyslipidaemia and DM

ODYSSEY Diabetes 2: ***Executive Committee member*** *(Completed 2017. Sanofi Regeneron)*
Phase 3 RCT assessing efficacy of Alirocumab on lipids in patients with DM treated with insulin

CLEAR Outcomes: ***Executive Committee member***
Efficacy of Bempedoic acid on LDL-C and CV Outcomes in statin-intolerant patients

CLEAR Harmony: ***Principal Investigator***
Efficacy and safety of Bempedoic acid on LDL-C in patients on maximally-tolerated statins

CLEAR LIPIDS: ***Executive Committee member***
Four Phase 3 Lipid-lowering trials of Bemepdoic acid

PROMINENT: ***Steering Committee member***
Efficacy & safety of Pemafibrate on CV events in patients with high Triglyceride levels and high risk of CVD

ORION-9: ***Chair of the Phase 3 programme and Executive Committee member***
Study of the safety and efficacy of the first siRNA therapy Inclisiran in FH patients

ORION-10: ***Chair of the Phase 3 programme and Executive Committee member***
Study of the safety and efficacy of the first siRNA therapy Inclisiran in patients with CVD

ORION-11: ***Principal Investigator***
Study of safety & efficacy of first siRNA therapy Inclisiran in patients with CVD/high-risk primary prevention

ORION-3: ***Principal Investigator***
Open Label Extension of ORION 1 comparing siRNA therapy Inclisiran to Monoclonal antibodies to PCSK9

ORION-8: Co-*Principal Investigator*
Open Label Extension of ORION 9,10 and 11 assessing long term safety of siRNA therapy (Inclisiran)

ORION-4: ***Executive Committee member***
Cardiovascular outcomes study of Inclisiran vs placebo in patients with high cardiovascular risk and elevated LDL cholesterol

PREVAIL: ***Executive Committee member***
Cardiovascular outcomes study of obicetrapib vs placebo in patients with high cardiovascular risk and elevated LDL cholesterol

VENTI: ***Executive Committee member***
A programme of several phase 3 trials of the first ASO directed therapy against PCSK9. Programme includes a CV outcomes trail and several Lipid lowering safety studies in patients with FH or high CV risk

Cohort Studies: Leadership

TIGRIS International Registry: ***National Lead Investigator***
Identifying the patterns of anti-platelet therapy and pharmacotherapy among patients with stable coronary disease, their impact on health service resource and CVD events

Heymans (2015-2021): ***Principal Investigator***
Real world study on the safety and efficacy of the first approved PCSK9 Mab (Evolocumab) for cholesterol-lowering in 12 European Countries. Prospective study of 2,000 patients

Da Vinci (2017-2018): ***Principal Investigator***
Assessing the use of lipid-lowering therapies and control of cholesterol across 18 European Countries. Cross-sectional-study of ~6,000 patients

TOGETHER e-health study: ***Principal Investigator***
Cross-sectional study of the burden of cardiovascular risk factors in NW London using NHS Health Checks

Familial Hypercholesterolaemia Studies Collaboration (FHSC): ***Principal Investigator***
Global registry of 72 countries and ~66,000 cases of FH to assess how FH is detected and managed and the consequences thereof

SANTORINI (2020-2021): ***Principal Investigator***
European Registry of ~10,000 very high- and high-risk patients assessing implementation of the 2019 ESC Cholesterol Guidelines-Prospective Cohort Study

MILOS: ***Steering Committee Member***
Assessing real world use of bempedoic acid in Europe

INTERASPIRE: ***Executive Committee member***
Assessing management and approaches to risk factor management post myocardial infarction across 5 WHO regions

Research Grants Awarded over the last 10 years

2022 **ZODIAC Trial.** ***Principal Investigator***
Initiated a trial assessing decision support tool impact on optimisation of lipid lowering within 24 weeks of a myocardial infarction
- £5.5 million, Sanofi

2020 **FH Studies Collaboration.** ***Principal Investigator***
- £180,000 Regeneron

2019 **Santorini Registry.** ***Principal Investigator***
Investigator-Initiated study
- €2.25 million Daiichi Sankyo

2019 **HDR UK.** ***Co-Lead***
Digital Innovation Hub
- £10 million

2019 **FH Studies Collaboration.** ***Principal Investigator***
- £500,000 Amgen

2019 **FH Studies Collaboration.** ***Principal Investigator***
- £180,000 Daiichi Sankyo

2017 **American Heart Association.** ***Principal Investigator***
- £190,000 (18 months) assessing apps to improve patient adherence to lifestyle and medication

2016 **Da Vinci.** ***Principal Investigator***
- £5.5 million (18 months) Amgen investigator-initiated grant for cross-sectional study of the management of high-risk EU patients

2016 **IAS Pfizer Independent grants for learning and change.** ***Principal Investigator***
- $205,000 (1 year) to establish a risk prediction tool for additional lipid lowering therapies

2015 **Sanofi.** ***Principal Investigator***
- £93,000 (1 year) for Statin Intolerance analyses from CPRD

2015 **MSD investigator initiated grant.** ***Principal Investigator***
- £260 000 (3 years) to establish the FH Studies Collaboration

2015 **Sanofi investigator initiated grant.** ***Principal Investigator***
- £260 000 (2 years) to establish the FH Studies Collaboration

2014 **Amgen investigator initiated grant.** ***Principal Investigator***
- £260 000 (2 years) to establish the FH Studies Collaboration

2014 **Pfizer global grants for dyslipidemia.** ***Principal Investigator***
- $175 000 over 1 year to establish a global collaborative registry of FH

2014 **Sanofi Unrestricted Research Grant.** ***Principal Investigator***
- £332,775 to collect NHS Vascular Health Checks in South London to establish a contemporary cohort of 200,000 participants. The TOGETHER study.

2014 **British Heart Foundation.**
- £96,000 application Collaboration with Mr Peter Holt, vascular surgery, St George's, an RCT of cardiac rehab among aortic aneurysm survivors to assess risk factor control vs usual care

2013 **SEMCARE European Union.** ***Co-Principal Investigator***
- €329,024 (*awarded start 2014*), a collaboration with Universities in Austria and Holland
- To assess systems for data extraction from electronic health records for population research

2013 **The Dunhill Medical Trust.** ***Co-applicant***
- £97,000 *(awarded start 2014)*, a collaboration with Mr Peter Holt, St George's